ŠPINAR, Jindřich, Lenka ŠPINAROVÁ, Filip MALEK, Ondřej LUDKA, Jan KREJČÍ, Petr OSTADAL, Dagmar VONDRAKOVA, Karel LÁBR, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Klára BENEŠOVÁ, Jiří JARKOVSKÝ and Jiří PAŘENICA. Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry. Plos one. San Francisco: Public Library of Science, 2019, vol. 14, No 3, p. 1-15. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0214363.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry
Authors ŠPINAR, Jindřich (203 Czech Republic, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Filip MALEK (203 Czech Republic), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Jan KREJČÍ (203 Czech Republic, belonging to the institution), Petr OSTADAL (203 Czech Republic), Dagmar VONDRAKOVA (203 Czech Republic), Karel LÁBR (203 Czech Republic, belonging to the institution), Monika ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, guarantor, belonging to the institution) and Jiří PAŘENICA (203 Czech Republic, belonging to the institution).
Edition Plos one, San Francisco, Public Library of Science, 2019, 1932-6203.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.740
RIV identification code RIV/00216224:14110/19:00109546
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1371/journal.pone.0214363
UT WoS 000462305600050
Keywords in English chronic heart failure
Tags 14110115, 14110211, 14110518, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 09:14.
Abstract
Background According to guidelines, the prognosis of patients with chronic heart failure can be predicted by determining the levels of natriuretic peptides, the NYHA classification and comorbidities. The aim our work was to develop a prognostic score in chronic heart failure patients that would take account of patients' comorbidities, NYHA and NT-proBNP levels. Methods and results A total of 1,088 patients with chronic heart failure with reduced ejection fraction (HFrEF) (LVEF<40%) and mid-range EF (HFmrEF) (LVEF 40-49%) were enrolled consecutively. Two-year all-cause mortality, heart transplantation and/or LVAD implantation were defined as the primary endpoint (EP). The occurrence of EP was 14.9% and grew with higher NYHA, namely 4.9% (NYHA I), 11.4% (NYHA II) and 27.8% (NYHA III-IV) (p<0.001). The occurrence of EP was 3%, 10% and 15-37% in patients with NT-proBNP levels <= 125 ng/L, 126-1000 ng/L and >1000 ng/L respectively. Discrimination abilities of NYHA and NT-proBNP were AUC 0.670 (p<0.001) and AUC 0.722 (p<0.001) respectively. The predictive value of the developed clinical model, which took account of older age, advanced heart failure (NYHA III+IV), anaemia, hyponatraemia, hyperuricaemia and being on a higher dose of furosemide (>40 mg daily) (AUC 0.773; p<0.001) was increased by adding the NT-proBNP level (AUC 0.790). Conclusion The use of prediction models in patients with chronic heart failure, namely those taking account of natriuretic peptides, should become a standard in routine clinical practice. It might contribute to a better identification of a high-risk group of patients in which more intense treatment needs to be considered, such as heart transplantation or LVAD implantation.
Links
MUNI/A/1250/2017, interní kód MUName: Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii
Investor: Masaryk University, Category A
PrintDisplayed: 8/5/2024 13:24